Background Levosimendan is a relatively new cardiac inotropic agent with calcium sensitizing activity. This study was conducted to investigate the effects of levosimendan (L) and dobutamine (D) on renal function in patients hospitalized with decompensated heart failure (HF)
# The Author(s) 2013. This article is published with open access at Springerlink.com Abstract Renal ...
Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe...
International audienceWHAT IS KNOWN AND OBJECTIVE: Positive inotropic agents are frequently used in ...
Background Levosimendan is a relatively new cardiac inotropic agent with calcium sensitizing activit...
Background: Levosimendan, a calcium sensitizer, increases the sensitivity of the heart to calcium, t...
Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated by many speci...
To assess the clinical outcomes of levosimendan and dobutamine in patients with acute decompensated ...
Renal dysfunction is common in clinical settings in which cardiac function is compromised such as he...
Renal dysfunction is common in clinical settings in which cardiac function is compromised such as he...
Renal dysfunction is common in clinical settings in which cardiac function is compromised such as he...
Levosimendan is a new agent for the treatment of acute heart failure. Levosimendan acts via compleme...
Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated by many speci...
Heart failure is characterised by decreased cardiac output, which results in the development of both...
In heart failure, positive inotropes that increase the heart's energy requirements (digoxin, phospho...
Classic inotropic agents provide short-term haemodynamic improvement in patients with heart failure,...
# The Author(s) 2013. This article is published with open access at Springerlink.com Abstract Renal ...
Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe...
International audienceWHAT IS KNOWN AND OBJECTIVE: Positive inotropic agents are frequently used in ...
Background Levosimendan is a relatively new cardiac inotropic agent with calcium sensitizing activit...
Background: Levosimendan, a calcium sensitizer, increases the sensitivity of the heart to calcium, t...
Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated by many speci...
To assess the clinical outcomes of levosimendan and dobutamine in patients with acute decompensated ...
Renal dysfunction is common in clinical settings in which cardiac function is compromised such as he...
Renal dysfunction is common in clinical settings in which cardiac function is compromised such as he...
Renal dysfunction is common in clinical settings in which cardiac function is compromised such as he...
Levosimendan is a new agent for the treatment of acute heart failure. Levosimendan acts via compleme...
Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated by many speci...
Heart failure is characterised by decreased cardiac output, which results in the development of both...
In heart failure, positive inotropes that increase the heart's energy requirements (digoxin, phospho...
Classic inotropic agents provide short-term haemodynamic improvement in patients with heart failure,...
# The Author(s) 2013. This article is published with open access at Springerlink.com Abstract Renal ...
Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe...
International audienceWHAT IS KNOWN AND OBJECTIVE: Positive inotropic agents are frequently used in ...